



NDA 210745/Original-1  
NDA 210745/Original-2

## NDA APPROVAL

Amgen Inc.  
Attention: Ericka Lassair, PharmD, PMP  
Manager, Regulatory Affairs  
1 Amgen Center Drive  
Thousand Oaks, CA 91320 USA

Dear Dr. Lassair:

Please refer to your new drug application (NDA) dated and received October 30, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA), for Otezla (apremilast) extended-release (XR) tablets.

This NDA provides for the use of Otezla (apremilast) XR tablets for the indications of:

- Adult patients with:
  - active psoriatic arthritis (PsA)
  - plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy
  - oral ulcers associated with Behçet's disease
- Pediatric patients 6 years of age and older and weighing at least 50 kg with:
  - active PsA
  - moderate to severe PsO who are candidates for phototherapy or systemic therapy

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Prescribing Information) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 210745.**” Approval of this submission by FDA is not required before the labeling is used.

### **DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for Otezla XR (apremilast) extended-release tablets shall be 24 months 20°C to 25°C (68°F to 77°F) for drug product in (b) (4) blisters and 36 months from the date of manufacture when stored at 20°C to 25°C (68°F to 77°F) when packaged in high-density polyethylene bottles.

### **ADVISORY COMMITTEE**

Your application for Otezla XR was not referred to an FDA advisory committee because this drug is not the first in its class.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to less than 6 years of age because necessary studies are impossible or highly impracticable.

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

We are deferring submission of your studies for pediatric patients 6 to 17 years of age who weigh 20 kg to 50 kg for this application because this product is ready for approval for use in adults and pediatric patients weighing greater than 50 kg; and the studies for use in pediatric patients weighing 20 kg to 50 kg have not been completed.

Your deferred pediatric studies required by section 505B(a) of the Federal Food, Drug, and Cosmetic Act/FDCA are required postmarketing studies. The status of these postmarketing studies must be reported annually according to 21 CFR 314.81 and section 505B(a)(4)(C) of the Federal Food, Drug, and Cosmetic Act/FDCA. These required studies are listed below.

4885-1      Develop an age appropriate extended-release formulation suitable for use in pediatric patients who weigh 20 kg to 50 kg.

Final Report Submission:                      09/2026

4885-2      Conduct a relative bioavailability study in healthy adult subjects to determine an appropriate dose and dosing regimen for the use of extended-release apremilast formulation in pediatric patients aged 6 to 17 years weighing 20 kg to 50 kg for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.

Final Protocol Submission:                      08/2026

Study Completion:                                      05/2027

Final Report Submission:                      02/2028

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.<sup>3</sup>

Submit the protocols to IND 070270 and IND 121919, with a cross-reference letter to this NDA. Reports of these required pediatric postmarketing studies) must be submitted as an NDA or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from this/these studies. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

---

<sup>3</sup> See the guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (October 2019)*.  
<https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>4</sup>

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>5</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>6</sup>

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

## **COMPENDIAL STANDARDS**

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website<sup>7</sup>.

---

<sup>4</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>6</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

<sup>7</sup> <https://www.uspnf.com/>

If you have any questions, call the following Regulatory Project Managers:

For NDA 210745/Original 1 for treatment of patients with active psoriatic arthritis–Sadaf Nabavian at 301-796-2777

For NDA 210745/Original 2 for treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, and patients with oral ulcers associated with Behcet’s disease-Strother D. Dixon at 301-796-1015

Sincerely,

*{See appended electronic signature page}*

Raj Nair, MD  
Director  
Division of Rheumatology and Transplant  
Medicine  
Office of Immunology and Inflammation  
Office of New Drugs  
Center for Drug Evaluation and Research

Tatiana Oussova, MD, MPH  
Deputy Director for Safety  
Division of Dermatology and Dentistry  
Office of Immunology and Inflammation  
Office of New Drugs  
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
- Carton and Container Labeling

---

**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**

---

/s/  
-----

RAJ NAIR  
08/29/2025 01:19:13 PM

TATIANA OUSSOVA  
08/29/2025 01:23:00 PM